Article in The Journal of experimental medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
20 authors.
Xin GengCardiovascular Biology Research Program, Oklahoma Medical Research Foundation , Oklahoma City, OK, USA.ORCID 0009-0007-8743-7510
Lijuan Chen *Cardiovascular Biology Research Program, Oklahoma Medical Research Foundation , Oklahoma City, OK, USA.ORCID 0009-0009-2961-3664
Zoheb Ahmed *Cardiovascular Biology Research Program, Oklahoma Medical Research Foundation , Oklahoma City, OK, USA.ORCID 0009-0008-0409-8072
Guilherme Pedron FormigariCardiovascular Biology Research Program, Oklahoma Medical Research Foundation , Oklahoma City, OK, USA.ORCID 0000-0002-8028-7480
Yen-Chun HoCardiovascular Biology Research Program, Oklahoma Medical Research Foundation , Oklahoma City, OK, USA.ORCID 0000-0001-9147-2502
Ilaria Del GaudioUniversité Paris Cité, Inserm, Paris Research Center-Cardiovascular (PARCC) , Paris, France.ORCID 0000-0001-6794-8291
Marcella Neves DatiloCardiovascular Biology Research Program, Oklahoma Medical Research Foundation , Oklahoma City, OK, USA.ORCID 0000-0001-6763-3337
Zheila J Azartash-NaminCardiovascular Biology Research Program, Oklahoma Medical Research Foundation , Oklahoma City, OK, USA.ORCID 0009-0002-1396-5445
Coraline HeronUniversité Paris Cité, Inserm, Paris Research Center-Cardiovascular (PARCC) , Paris, France.ORCID 0000-0002-3376-0685
Xindi ShanCardiovascular Biology Research Program, Oklahoma Medical Research Foundation , Oklahoma City, OK, USA.ORCID 0000-0003-3951-8766
Ravi Shankar KeshariCardiovascular Biology Research Program, Oklahoma Medical Research Foundation , Oklahoma City, OK, USA.ORCID 0000-0002-4177-9095
Soumiya PalDepartment of Medical Pharmacology and Physiology, University of Missouri, Columbia, MO, USA.ORCID 0000-0002-8003-9866
Hong ChenVascular Biology Program, Boston Children's Hospital , Boston, MA, USA.ORCID 0000-0002-1906-6611
Florea LupuCardiovascular Biology Research Program, Oklahoma Medical Research Foundation , Oklahoma City, OK, USA.ORCID 0000-0003-1249-9278
Lijun XiaCardiovascular Biology Research Program, Oklahoma Medical Research Foundation , Oklahoma City, OK, USA.ORCID 0000-0002-9586-7971
Gwendalyn J RandolphDepartment of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO, USA.ORCID 0000-0001-9045-1195
Scott D ZawiejaDepartment of Medical Pharmacology and Physiology, University of Missouri, Columbia, MO, USA.ORCID 0000-0003-4658-3179
Eric CamererUniversité Paris Cité, Inserm, Paris Research Center-Cardiovascular (PARCC) , Paris, France.ORCID 0000-0002-6271-7125
Michael J DavisDepartment of Medical Pharmacology and Physiology, University of Missouri, Columbia, MO, USA.ORCID 0000-0002-7992-9300
R Sathish SrinivasanCardiovascular Biology Research Program, Oklahoma Medical Research Foundation , Oklahoma City, OK, USA.ORCID 0000-0002-4465-3340
Funding
Viral sensor IFIH1 promotes SLE through an altered interferon programP20GM139763 · NIGMS · OKLAHOMA MEDICAL RESEARCH FOUNDATION · PI Rajanarayanan S Srinivasan · 2021 to 2026
$20.3M
Pilot Projects ProgramP30GM149376 · NIGMS · OKLAHOMA MEDICAL RESEARCH FOUNDATION · PI Linda F Thompson · 2023 to 2026
$7.4M
Molecular Mechanisms Controlling Lymphatic Vascular Function in Health and DiseaseR01HL133216 · NHLBI · BOSTON CHILDREN'S HOSPITAL · PI CHEN, HONG, DIXON, JAMES BRANDON · 2016 to 2025
$6.7M
Lymphatic pacemaking and pumping in lymphedema: function, dysfunction, and rescueR01HL122578 · NHLBI · UNIVERSITY OF MISSOURI-COLUMBIA · PI DAVIS, MICHAEL JOHN · 2015 to 2023
$4.1M
Defining the Mechanisms of Lymphatic Vascular Growth and FunctionR01HL131652 · NHLBI · OKLAHOMA MEDICAL RESEARCH FOUNDATION · PI SRINIVASAN, RAJANARAYANAN S · 2016 to 2025
$3.9M
Novel lymphatic genes that regulate heart valve development and diseaseR01HL163095 · NHLBI · OKLAHOMA MEDICAL RESEARCH FOUNDATION · PI Rajanarayanan S Srinivasan · 2023 to 2026
$2.2M
Site-1 protease-mediated lipid metabolism in lymphatic vascular developmentR01HL153728 · NHLBI · OKLAHOMA MEDICAL RESEARCH FOUNDATION · PI XIA, LIJUN · 2020 to 2023
$1.7M
Regulation of lymphatic muscle cell function by store operated calcium entry signalingR01HL175083 · NHLBI · UNIVERSITY OF MISSOURI-COLUMBIA · PI Scott D. Zawieja · 2024 to 2026
$1.7M
French National Research Agency ANR-19-CE14-0028-01French National Research Agency ANR-23-CE14-0035-2National Heart, Lung and Blood Institute R01HL122578National Heart, Lung and Blood Institute R01HL131652National Heart, Lung and Blood Institute R01HL133216National Heart, Lung and Blood Institute R01HL153728National Heart, Lung and Blood Institute R01HL163095National Heart, Lung and Blood Institute R01HL175083NHLBI NIH HHS R01 HL122578NHLBI NIH HHS R01 HL131652NHLBI NIH HHS R01 HL133216NHLBI NIH HHS R01 HL153728NHLBI NIH HHS R01 HL163095NHLBI NIH HHS R01 HL175083NIGMS NIH HHS P20 GM139763NIGMS NIH HHS P30 GM149376NIH HHSOklahoma Center for Adult Stem Cell ResearchTobacco Settlement Endowment Trust 4340
6 · The paper itself
Abstract
Efficient lymph flow is ensured by lymphatic valves (LVs). The mechanisms that regulate LV development are incompletely understood. Here, we show that the deletion of the GPCR sphingosine 1-phosphate receptor-1 (S1PR1) from lymphatic endothelial cells (LECs) results in fewer LVs. Interestingly, LVs that remained in the terminal ileum-draining lymphatic vessels were specifically dysfunctional. Furthermore, tertiary lymphoid organs (TLOs) formed in the terminal ileum of the mutant mice. TLOs in this location are associated with ileitis in humans and mice. However, mice lacking S1PR1 did not develop obvious characteristics of ileitis. Mechanistically, S1PR1 regulates shear stress signaling and the expression of the valve-regulatory molecules FOXC2 and connexin-37. Importantly, Foxc2+/- mice, a model for lymphedema-distichiasis syndrome, also develop TLOs in the terminal ileum. Thus, we have discovered S1PR1 as a previously unknown regulator of LV and TLO development. We also suggest that TLOs are a sign of subclinical inflammation that can form due to lymphatic disorders in the absence of ileitis.
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
S1PR1 regulates lymphatic valve development and tertiary lymphoid organ formation in the ileum. · full record | OpenQuestion